Author:
Bordeianu Gabriela,Mitu Ivona,Stanescu Raluca Stefania,Ciobanu Corina Paraschiva,Petrescu-Danila Elena,Marculescu Afrodita Doina,Dimitriu Daniela Cristina
Abstract
Atherosclerosis is still considered a disease burden with long-term damaging processes towards the cardiovascular system. Evaluation of atherosclerotic stages requires the use of independent markers such as those already considered traditional, that remain the main therapeutic target for patients with atherosclerosis, together with emerging biomarkers. The challenge is finding models of predictive markers that are particularly tailored to detect and evaluate the evolution of incipient vascular lesions. Important advances have been made in this field, resulting in a more comprehensible and stronger linkage between the lipidic profile and the continuous inflammatory process. In this paper, we analysed the most recent data from the literature studying the molecular mechanisms of biomarkers and their involvement in the cascade of events that occur in the pathophysiology of atherosclerosis.
Reference157 articles.
1. New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease;Lorenzatti;Eur. Cardiol. Rev.,2020
2. The changing landscape of atherosclerosis;Libby;Nature,2021
3. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment;Carr;Pathology,2019
4. Measuring LDL-cholesterol: What is the best way to do it?;Wolska;Curr. Opin. Cardiol.,2020
5. Gąsecka, A., Rogula, S., Szarpak, Ł., and Filipiak, K.J. (2021). LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis. Life, 11.